Altre lingue Aclaris Therapeutics, Inc.

Azioni

ACRS

US00461U1051

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 22/04/2024			Variaz. 5gg	Var. 1 gen.
1,22 ^USD	-1,61%		+0,83%	+16,19%

19/03	Aclaris Therapeutics, Inc. annuncia le dimissioni dal Consiglio di Amministrazione	CI
27/02	Aclaris Therapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Aclaris Therapeutics, Inc. Announces Board Resignations	19/03
Aclaris: Q4 Earnings Snapshot	27/02
Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023	27/02
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q4 Revenue $17.6M	27/02
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	27/02
Aclaris Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
North American Morning Briefing : Stock Futures -2-	21/02
Aclaris Therapeutics, Inc. Announces Termination of Employment of Gail Cawkwell as Chief Medical Officer	05/02
North American Morning Briefing : Stock Futures -2-	23/01
Sector Update: Health Care Stocks Weaker Late Afternoon	16/01
Sector Update: Health Care Stocks Softer Tuesday Afternoon	16/01
Aclaris Therapeutics Shares Rise; Strategic Review Announced, CEO Manion to Step Down	16/01
Aclaris Therapeutics Conducts Strategic Review of Business	16/01
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review	16/01
Aclaris Therapeutics, Inc. Announces Executive Changes	16/01
Aclaris Therapeutics, Inc. Announces Chief Executive Officer Changes	16/01
North American Morning Briefing : Stock Futures -2-	12/01
Top Midday Decliners	10/01
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis	10/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Aclaris Therapeutics, Inc.

Azioni

ACRS

US00461U1051

Altre lingue

Filtri